Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the r...
Saved in:
| Published in: | Emerging infectious diseases Vol. 27; no. 1; pp. 332 - 334 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
U.S. National Center for Infectious Diseases
01-01-2021
Centers for Disease Control and Prevention |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose. |
|---|---|
| AbstractList | The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose. |
| Audience | Professional Academic |
| Author | Peloquin, Charles Macias, Patricia Jones, Betsy A Rowlinson, Marie-Claire Jaimon, Roshni Jasuja, Supriya Darnall, Elaine Goswami, Neela D Gomez, Maria E Haley, Connie A Onderko, Pennelyn Ashkin, David |
| Author_xml | – sequence: 1 givenname: Connie A surname: Haley fullname: Haley, Connie A – sequence: 2 givenname: Patricia surname: Macias fullname: Macias, Patricia – sequence: 3 givenname: Supriya surname: Jasuja fullname: Jasuja, Supriya – sequence: 4 givenname: Betsy A surname: Jones fullname: Jones, Betsy A – sequence: 5 givenname: Marie-Claire surname: Rowlinson fullname: Rowlinson, Marie-Claire – sequence: 6 givenname: Roshni surname: Jaimon fullname: Jaimon, Roshni – sequence: 7 givenname: Pennelyn surname: Onderko fullname: Onderko, Pennelyn – sequence: 8 givenname: Elaine surname: Darnall fullname: Darnall, Elaine – sequence: 9 givenname: Maria E surname: Gomez fullname: Gomez, Maria E – sequence: 10 givenname: Charles surname: Peloquin fullname: Peloquin, Charles – sequence: 11 givenname: David surname: Ashkin fullname: Ashkin, David – sequence: 12 givenname: Neela D surname: Goswami fullname: Goswami, Neela D |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33227229$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1vEzEQhleoiH7AlSOKhIRAYoO_1t69IFWFQqRCpTblatne8cbRZl1sbwX_HpeE0KAckA-2xs-8nhm_x8XB4AcoiucYTSlB-B24lgiEpwRRwfmj4gijGpUcVc3B9szQYXEc4xIhnFOaJ8UhpYQIQpqj4vyrv4N-wssvfkiLyTyASisY0sT6MPkQxq68guhiUjk0HzUEM_Y-B95ObgaXoJ1cJ5UgPi0eW9VHeLbZT4qb84_zs8_lxeWn2dnpRWl4XadSaKqQbgwGbg2qjKYa21Zbq6u2IVQ1SDWmbiiroDIVoQQLZWuMayoQryijJ8Vsrdt6tZS3wa1U-Cm9cvJ3wIdOqpCc6UG2goEmzLSNNUxwpi1jtMWYYzAGa5213q-1bke9gtbkroPqd0R3bwa3kJ2_k0IIVtUkC7zeCAT_fYSY5MpFA32vBvBjlIRxhhnHtcjoy3_QpR_DkEeVqVqQRlSY_6U6lRtwg_X5XXMvKk957qEieYqZKvdQHQyQi8zusC6Hd_jpHj6vFlbO7E14s5OQmQQ_UqfGGOXs-ur_2ctvu-yrB-wCVJ8W0fdjcn6Ieys2wccYwG4_BSN5b3u5sb1c2z4nvHj4lVv8j8_pL65U-nU |
| CitedBy_id | crossref_primary_10_1128_aac_01562_23 crossref_primary_10_1016_j_jinf_2023_01_039 crossref_primary_10_1111_tmi_13867 crossref_primary_10_1093_cid_ciad312 crossref_primary_10_12677_ACM_2023_1371632 crossref_primary_10_2147_DDDT_S281639 crossref_primary_10_1016_j_drudis_2023_103693 crossref_primary_10_1080_24745332_2023_2226006 crossref_primary_10_1097_MD_0000000000030405 crossref_primary_10_1093_ofid_ofad534 crossref_primary_10_1080_24745332_2022_2039499 crossref_primary_10_1128_spectrum_02405_23 crossref_primary_10_1177_20499361231188039 crossref_primary_10_1056_NEJMc2119461 crossref_primary_10_1128_jcm_01634_22 crossref_primary_10_1016_j_cmi_2021_08_007 crossref_primary_10_1128_aac_00035_23 crossref_primary_10_1128_AAC_01545_21 crossref_primary_10_4103_lungindia_lungindia_72_23 crossref_primary_10_1021_acs_oprd_3c00287 |
| Cites_doi | 10.1128/mBio.01741-15 10.1056/NEJMoa1201964 10.1164/rccm.201909-1874ST 10.1056/NEJMoa1901814 10.1016/j.ijantimicag.2018.10.012 10.1016/j.ebiom.2015.09.051 10.1007/s40265-019-01207-9 10.1128/AAC.00239-17 10.1016/S2213-2600(19)30418-7 10.1128/microbiolspec.TNMI7-0029-2016 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 U.S. National Center for Infectious Diseases Published 2021. This article is a U.S. Government work and is in the public domain in the USA. |
| Copyright_xml | – notice: COPYRIGHT 2021 U.S. National Center for Infectious Diseases – notice: Published 2021. This article is a U.S. Government work and is in the public domain in the USA. |
| DBID | NPM AAYXX CITATION IOV ISR 3V. 7RV 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU FYUFA GHDGH K9- K9. KB0 M0R M0S NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.3201/eid2701.203766 |
| DatabaseName | PubMed CrossRef Opposing Viewpoints Resource Center Science (Gale in Context) ProQuest Central (Corporate) Proquest Nursing & Allied Health Source Health & Medical Complete (ProQuest Database) ProQuest Central (purchase pre-March 2016) ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Consumer Health Database Health & Medical Collection (Alumni Edition) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef ProQuest Public Health ProQuest Central Essentials ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Public Health PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| DocumentTitleAlternate | Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States |
| EISSN | 1080-6059 |
| EndPage | 334 |
| ExternalDocumentID | oai_doaj_org_article_d74eb24cd9fc4764bf443d1161ecc1bb A647652688 10_3201_eid2701_203766 33227229 |
| Genre | Journal Article Correspondence |
| GeographicLocations | United States Florida United States--US Illinois |
| GeographicLocations_xml | – name: United States – name: Florida – name: United States--US – name: Illinois |
| GroupedDBID | --- -~X .GJ 0ZS 186 29G 2WC 36B 53G 5GY 5VS 6PF 7RV 7X7 85S 8C1 8FI 8FJ 9K5 A8Z AAWTL AAYOK ABDBF ABUWG ACGFO ACZ ADBBV ADRAZ AEGXH AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC B0M BAWUL BCNDV BENPR C1A CCPQU DIK DO4 E3Z EAD EAP EAS EBC EBD EBS EDH EJD EMB EMH EMI EMK EMOBN EPL EPT ESTFP ESX F5P FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IBB IEA IEP IHR IHW IMI INH INR IOF IOV IPO ISR ITC K9- KQ8 M0R M48 M~E NAPCQ NEJ NPM O5R O5S OK1 P2P PGMZT PV9 Q.E QF4 QM9 QN7 QO4 Q~Q RGD RGQ RNS RPM RXW RZL SV3 TAE TR2 TUS TWZ UKHRP UQL W2D WH7 WOQ WOW XJT XSB YRT YV5 YXF ZBA ZGI ~8M AAYXX CITATION 3V. 7XB 8FK K9. PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c688t-7b3a0b9c1e6fc05cb3b1fdbffb5d923a90a9c89345e5c523217af811837065343 |
| IEDL.DBID | RPM |
| ISSN | 1080-6040 |
| IngestDate | Tue Oct 22 15:09:29 EDT 2024 Tue Sep 17 21:14:38 EDT 2024 Sat Aug 17 00:20:23 EDT 2024 Thu Oct 10 20:40:02 EDT 2024 Tue Nov 19 20:55:45 EST 2024 Thu Nov 14 21:17:25 EST 2024 Tue Nov 12 23:09:13 EST 2024 Thu Aug 01 20:17:28 EDT 2024 Thu Aug 01 19:28:19 EDT 2024 Tue Aug 20 22:14:03 EDT 2024 Thu Sep 26 19:07:56 EDT 2024 Sat Sep 28 08:23:21 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | linezolid bacteria United States antimicrobial resistance BPaL Nix-TB drug monitoring tuberculosis and other mycobacteria pretomanid bedaquiline |
| Language | English |
| License | This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c688t-7b3a0b9c1e6fc05cb3b1fdbffb5d923a90a9c89345e5c523217af811837065343 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774582/ |
| PMID | 33227229 |
| PQID | 2487297516 |
| PQPubID | 105375 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d74eb24cd9fc4764bf443d1161ecc1bb pubmedcentral_primary_oai_pubmedcentral_nih_gov_7774582 proquest_miscellaneous_2464146187 proquest_journals_2487297516 gale_infotracmisc_A647652688 gale_infotracgeneralonefile_A647652688 gale_infotracacademiconefile_A647652688 gale_incontextgauss_ISR_A647652688 gale_incontextgauss_IOV_A647652688 gale_healthsolutions_A647652688 crossref_primary_10_3201_eid2701_203766 pubmed_primary_33227229 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-00 20210101 2021-01-01 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Emerging infectious diseases |
| PublicationTitleAlternate | Emerg Infect Dis |
| PublicationYear | 2021 |
| Publisher | U.S. National Center for Infectious Diseases Centers for Disease Control and Prevention |
| Publisher_xml | – name: U.S. National Center for Infectious Diseases – name: Centers for Disease Control and Prevention |
| References | Song (key-10.3201/eid2701.203766-202012211757-R9) 2015; 2 Nahid (key-10.3201/eid2701.203766-202012211757-R5) 2019; 200 Conradie (key-10.3201/eid2701.203766-202012211757-R1) 2020; 382 Keam (key-10.3201/eid2701.203766-202012211757-R2) 2019; 79 Brown (key-10.3201/eid2701.203766-202012211757-R4) 2015; 6 Peloquin (key-10.3201/eid2701.203766-202012211757-R7) 2017; 5 Lee (key-10.3201/eid2701.203766-202012211757-R3) 2012; 367 Heinrichs (key-10.3201/eid2701.203766-202012211757-R8) 2019; 53 Harding (key-10.3201/eid2701.203766-202012211757-R10) 2020; 8 Xu (key-10.3201/eid2701.203766-202012211757-R6) 2017; 61 |
| References_xml | – volume: 6 start-page: e01741 year: 2015 ident: key-10.3201/eid2701.203766-202012211757-R4 article-title: Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. publication-title: MBio doi: 10.1128/mBio.01741-15 contributor: fullname: Brown – volume: 367 start-page: 1508 year: 2012 ident: key-10.3201/eid2701.203766-202012211757-R3 article-title: Linezolid for treatment of chronic extensively drug-resistant tuberculosis. publication-title: N Engl J Med doi: 10.1056/NEJMoa1201964 contributor: fullname: Lee – volume: 200 start-page: e93 year: 2019 ident: key-10.3201/eid2701.203766-202012211757-R5 article-title: Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201909-1874ST contributor: fullname: Nahid – volume: 382 start-page: 893 year: 2020 ident: key-10.3201/eid2701.203766-202012211757-R1 article-title: Treatment of highly drug-resistant pulmonary tuberculosis. publication-title: N Engl J Med doi: 10.1056/NEJMoa1901814 contributor: fullname: Conradie – volume: 53 start-page: 275 year: 2019 ident: key-10.3201/eid2701.203766-202012211757-R8 article-title: Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2018.10.012 contributor: fullname: Heinrichs – volume: 2 start-page: 1627 year: 2015 ident: key-10.3201/eid2701.203766-202012211757-R9 article-title: Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. publication-title: EBioMedicine doi: 10.1016/j.ebiom.2015.09.051 contributor: fullname: Song – volume: 79 start-page: 1797 year: 2019 ident: key-10.3201/eid2701.203766-202012211757-R2 article-title: Pretomanid: first approval. publication-title: Drugs doi: 10.1007/s40265-019-01207-9 contributor: fullname: Keam – volume: 61 start-page: e00239-17 year: 2017 ident: key-10.3201/eid2701.203766-202012211757-R6 article-title: Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00239-17 contributor: fullname: Xu – volume: 8 start-page: 19 year: 2020 ident: key-10.3201/eid2701.203766-202012211757-R10 article-title: WHO global progress report on tuberculosis elimination. publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(19)30418-7 contributor: fullname: Harding – volume: 5 year: 2017 ident: key-10.3201/eid2701.203766-202012211757-R7 article-title: The role of therapeutic drug monitoring in mycobacterial infections. publication-title: Microbiol Spectr doi: 10.1128/microbiolspec.TNMI7-0029-2016 contributor: fullname: Peloquin |
| SSID | ssj0012019 |
| Score | 2.4959114 |
| Snippet | The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 332 |
| SubjectTerms | antimicrobial resistance bedaquiline Biopsy Care and treatment Chemotherapy Diagnosis Disease control Dosage and administration Drug dosages drug monitoring Drug resistance Extensively drug-resistant tuberculosis FDA approval Infectious diseases Linezolid Medical laboratories Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States Patient outcomes Patients Pharmacy pretomanid Protein synthesis Public health Research Letter Tuberculosis tuberculosis and other mycobacteria |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgJySE-CZQaECIXojqxI7tHEvbFVyK1C6ImxU79rZSlaDNht_PTJwNtUCih17tF-1qxh7PS8ZvCHlfmVJSoXwGp5HJuDFNVtWWZiXGS2tqVpixie25PP2hjk9QJmdu9YU1YUEeOBjuoJEcyB-3TeUtl4IbzzlrckhU4MdzY8boS8WWTE3fD-BYq0JpPZAjWKdBrpHB8IG7bApJkRqyoI345zgaVfv_js3XDqe4cPLaSbR4SB5MKWR6GP76I3LHtY_J_fD-LQ3Xip6QxWn3y12lIoNNu7lIl9t68hSS1PR4PayyM9dj7ghDy8G4tR2uOhj4mIYsNA1Z6FPybXGyPPqcTT0TMiuU2mTSsJqayuZOeEtLa5jJfWO8N2UDuVxd0bqykKPw0pUWSCgwktorYBkMv3cyzp6RnbZr3QuSVtyVTDhDuTfc5mB5qiT3NXYYc7mkCdnfmk7_DNIYGigFGllPRtbByAn5hJadUShpPQ6Ao_XkaP0_RydkD_2iw_3QeWPqQwFoFK1RCXk3IlDWosW6mVU99L3-8vX7DUDnZxFofwL5Dhxt6-muAhgG5bIi5IcIuQpi4f8C7kZA2MU2nt4uNz1FkV4XwCbx5nMOFnw7T-OTWBnXum5AjODYm13JhDwPq3O2M4NoLYuiSoiM1m3kiHimvbwYNcYl0IJSFS9vw3OvyL0CK4HGF1e7ZGezHtxrcrdvhjfjrv0NrrREgA priority: 102 providerName: Directory of Open Access Journals |
| Title | Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33227229 https://www.proquest.com/docview/2487297516 https://search.proquest.com/docview/2464146187 https://pubmed.ncbi.nlm.nih.gov/PMC7774582 https://doaj.org/article/d74eb24cd9fc4764bf443d1161ecc1bb |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYnpAQojxTSgkI0QvpOrETJ8fSdgUHCmoXxM2KHXu70japNpv-fmbsZGkEB8TV_qJE4xn7G2cehLwrVCpoltsITiMVcaWqqCg1jVLcL7UqWaJcE9tLcf4zPz3DMjnpkAvjgva1Wh7Vq-ujennlYitvrvV0iBObfvtyIoCzpHkynZAJcMPBRe9_HcCJVvioevCLQEV9pUYGw1OzrBJB0SsEs8LmRQzUWSSOXv4-lFzt_j936DtH1Dh88s55NHtEHvZEMjz2H7xL7pn6MXngb-FCn1z0hMzOm1uzCrMITHdzFc6HqPIQqGp4uu4W0YVpkUHC0LxTZq27VQMDH0LPRUPPRZ-S77Oz-cmnqO-cEOkszzeRUKykqtCxyaymqVZMxbZS1qq0AkZXFrQsNDAVnppUgysKfklpc_A1GP71ZJw9Izt1U5sXJCy4SVlmFOVWcR1zZWkuuC2xz5iJBQ3I4SA6eeMLZEhwLFDespe39PIOyEeU7BaFha3dQLNeyH55ZSU4-PpcV4XVXGTwOs5ZFQMvBV2LlQrIa1wX6bNEt-YpjzNAY-maPCBvHQKLW9QYPbMou7aVn7_--AfQ5cUIdNiDbAMLrcs-YwEEg0WzRsj3I-TClwz_G3B_BARb1uPpQd1kv5e0MgGfEvOfY5Dgm-00PonxcbVpOsRkHDu05yIgz712buU8KHlAxEhvRwsxngHDc5XGe0Pb--8nX5L7CQYBuTurfbKzWXfmFZm0VXfgbj8OnO3-AvBfRNc |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoOYCEeD8ChQaE6IV0ncSJk2Npu2pFu6B2qbhZsWNvV9om1WbD72fGTpZGcEC92l-0Ws-M55tkHoR8zGXCaZqZALyRDJiUZZAXigYJ3pdKFnEk7RDbcz75mR0cYpucpK-FsUn7Ss53q8XVbjW_tLmV11dq1OeJjb6f7nPgLEkWjTbIXbBXSvsgvft4AD4td3n1EBmBkrpejTEsj_S8jDjFuBAMC8cXxaDQPLIE849bst37_76jbzipYQLlDY80fnTL__KYPOwoqL_ntp-QO7p6Sh6493e-K0t6RsaT-pde-GkARr-69Kd9ProPJNc_WLaz4Ew3yD1hadpKvVTtooaFz75jsb5jsc_Jj_HhdP8o6GYuBCrNslXAZVxQmatQp0bRRMlYhqaUxsikBC5Y5LTIFXAcluhEQRALEU1hMohSYvxeGrP4Bdms6kq_In7OdBKnWlJmJFMhk4ZmnJkCJ5TpkFOP7PRHLq5daw0BIQnKSXRyEk5OHvmCElmjsCW2XaiXM9Edpig50zJiqsyNYjyFn2MsLkNgtKCloZQe2UZ5CldfujZssZcCGpveZB75YBHYFqPCvJtZ0TaNOP528R-g87MBaKcDmRoURBVdrQMcDLbbGiA_DZAz12z8X8CtARBuATXc7tVUdLdQIyKIRrFyOoQTfL_exicxs67SdYuYlOFs94x75KXT6vU598bhET7Q94Eghjug5rZHeafWr2_95Da5dzQ9PREnx5Ovb8j9CFOJ7JuvLbK5Wrb6LdloyvadtfzfWDJZcg |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYkBASGt-QMVhAiL2Q5cuJk8exrmICyrSViTcrduyuUpdUTcPfz52dlEXwgODV_kVV78P3u-R8R8jbXCQsSDPtQTQSHhWi9PJCBl6C56UURRwJM8T2gk2-Z6MTbJOzGfVlivalmB9Wi-vDan5laiuX19Lv68T8sy_HDDhLkkX-stT-FrkNPhtEfaLefUCAuJbb2nrIjsBQbb_GGJZ9NS8jFmBuCM6FI4xiMGoWGZL5KzSZDv6_n9M3AtWwiPJGVBrf_4__84DsdFTUPbKQh-SWqh6Re_Y9nmuvJz0m40n9Qy3c1APnX1-5074u3QWy645W7cw7Vw1yUFiatkKtZLuoYeG9a9msa9nsE_JtfDI9_uh1sxc8mWbZ2mMiLgKRy1ClWgaJFLEIdSm0FkkJnLDIgyKXwHVoohIJySxkNoXOIFuJ8btpTOOnZLuqK_WcuDlVSZwqEVAtqAyp0EHGqC5wUpkKWeCQg17sfGlbbHBITVBXvNMVt7pyyAfUygaFrbHNQr2a8U6gvGRUiYjKMteSshR-jtK4DIHZgrWGQjhkH3XK7T3TjYPzoxTQ2Pwmc8gbg8D2GBXW38yKtmn46dfLvwBdnA9ABx1I12AksujuPIBgsO3WAPlugJzZpuN_Au4NgHAayOF2b6q8O40aHkFWijeoQ5Dg6802PokVdpWqW8SkFGe8Z8whz6xlb-TcO4hD2MDmB4oY7oCpm17lnWnv_vOT--TO2WjMP59OPr0gdyOsKDIvwPbI9nrVqpdkqynbV8b5fwIrDFvy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+6-Month+Treatment+for+Drug-Resistant+Tuberculosis%2C+United+States&rft.jtitle=Emerging+infectious+diseases&rft.au=Haley%2C+Connie+A&rft.au=Macias%2C+Patricia&rft.au=Jasuja%2C+Supriya&rft.au=Jones%2C+Betsy+A&rft.date=2021-01-01&rft.eissn=1080-6059&rft.volume=27&rft.issue=1&rft_id=info:doi/10.3201%2Feid2701.203766&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1080-6040&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1080-6040&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1080-6040&client=summon |